Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Caplin Point Laboratories Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 389 | 395 | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 |
| Expenses + | 265 | 269 | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 |
| Operating Profit | 124 | 127 | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 |
| OPM % | 32% | 32% | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% |
| Other Income + | 11 | 12 | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 11 | 11 | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 |
| Profit before tax | 124 | 127 | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 | 204 | 213 |
| Tax % | 18% | 18% | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% |
| Net Profit + | 101 | 104 | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 |
| EPS in Rs | 13.45 | 13.62 | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.10 | 20.32 | 21.56 | 22.38 |
Financials of Caplin Point Laboratories Ltd
Annual income statement trend
| Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 2,187 |
| Expenses + | 192 | 175 | 276 | 345 | 417 | 603 | 732 | 874 | 1,025 | 1,142 | 1,287 | 1,426 |
| Operating Profit | 60 | 64 | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 651 | 761 |
| OPM % | 24% | 27% | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% | 34% | 35% |
| Other Income + | 3 | 4 | 10 | 13 | 19 | 41 | 23 | 38 | 55 | 66 | 92 | 116 |
| Interest | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 53 | 66 | 73 |
| Profit before tax | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 | 677 | 803 |
| Tax % | 23% | 24% | 21% | 23% | 22% | 20% | 20% | 20% | 16% | 18% | 20% | 19% |
| Net Profit + | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 650 |
| EPS in Rs | 5.43 | 6.05 | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 84.36 |
| Dividend Payout % | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% | 8% | 8% | 5% |
Financials of Caplin Point Laboratories Ltd
Capital structure and asset base
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 78 | 113 | 210 | 349 | 582 | 858 | 954 | 1,252 | 1,649 | 2,084 | 2,619 | 3,571 |
| Borrowings + | 2 | 2 | 1 | 1 | 36 | 113 | 235 | 219 | 222 | 219 | 222 | 5 |
| Other Liabilities + | 134 | 137 | 133 | 136 | 109 | 139 | 159 | 250 | 305 | 380 | 352 | 454 |
| Total Liabilities | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,045 |
| Fixed Assets + | 113 | 144 | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 453 | 546 | 605 |
| CWIP | 31 | 0 | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 | 144 | 209 |
| Investments | 0 | 0 | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 | 590 | 859 |
| Other Assets + | 85 | 122 | 186 | 269 | 436 | 772 | 1,033 | 1,343 | 1,410 | 1,753 | 1,928 | 2,373 |
| Total Assets | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,045 |
Financials of Caplin Point Laboratories Ltd
Operating, investing and financing cash movement
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 50 | 42 | 68 | 66 | 83 | 45 | 269 | 337 | 271 | 318 | 432 | 523 |
| Cash from Investing Activity + | -23 | -6 | -36 | -69 | -100 | -54 | -30 | -377 | -216 | -319 | -333 | -582 |
| Cash from Financing Activity + | -9 | -14 | -7 | -12 | 90 | 80 | -24 | -41 | -28 | -38 | -38 | -46 |
| Net Cash Flow | 19 | 23 | 25 | -14 | 73 | 70 | 215 | -81 | 27 | -39 | 61 | -106 |
| Free Cash Flow | 24 | 34 | 43 | 18 | 18 | -32 | 195 | 246 | 78 | 173 | 241 | 275 |
| CFO/OP | 103% | 92% | 73% | 53% | 54% | 38% | 102% | 106% | 81% | 77% | 86% | 88% |
Financials of Caplin Point Laboratories Ltd
Working capital efficiency and return ratios
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 8 | 12 | 30 | 85 | 90 | 97 | 96 | 91 | 98 | 117 | 119 | 138 |
| Inventory Days | 37 | 57 | 44 | 44 | 47 | 210 | 139 | 149 | 159 | 183 | 159 | 181 |
| Days Payable | 112 | 168 | 155 | 144 | 76 | 57 | 68 | 102 | 84 | 116 | 103 | 125 |
| Cash Conversion Cycle | -67 | -99 | -81 | -16 | 61 | 251 | 166 | 138 | 173 | 184 | 175 | 194 |
| Working Capital Days | -128 | -114 | -29 | 47 | 104 | 167 | 145 | 165 | 144 | 166 | 174 | 263 |
| ROCE % | 68% | 62% | 68% | 63% | 45% | 33% | 28% | 28% | 26% | 26% | 26% | 25% |
CDMO division recorded its highest quarterly sales in the last 8 quarters, close to INR 400 crores, with a 33% growth over 9 months, indicating strong demand…
Capex for FY '24-'25 is largely complete, with INR 225 crores spent on the injectable unit to be capitalized. Key concall takeaways from Concord Biotech's Q3…
Domestic and international generic businesses continue to expand, with international growing 17% YoY. Key concall takeaways from Innova Captab's Q3 FY25…
INR 60 crores from Hyderabad plant in next 6 months, with some recovery from other units (Dahej, Jhagadia). Key concall takeaways from Sigachi Industries Ltd's…